Clinical-stage genetic-medicines company for neurological diseases.
Founders
Judith van Deutekom(Netherlands · ♀)— An RNA-modulating therapeutics scientist who led ASO drug discovery at Prosensa and BioMarin in the Netherlands, she spun out Vico to push antisense oligonucleotide therapies for rare neurological diseases.
Luc Dochez(Belgium · ♂)— A biotech executive and dealmaker from Belgium, he co-founded and chaired Vico to commercialize a new platform of genetic medicines for CNS disorders.
Josh Mandel-Brehm(United States · ♂)— A US biotech entrepreneur experienced in RNA and neuroscience ventures, he helped co-found Vico to build antisense therapies for central nervous system diseases.
Gail Mandel(United States · ♀)— A neuroscientist whose academic work on Rett syndrome and neuronal gene regulation underpinned the company's scientific approach to genetic CNS diseases.
Members see the full profile
Create a free EquityFlow account to see Vico Therapeutics's 2 funding rounds, 5 investors, 12 similar companies.